GET DAILY SIGNALSWhy Is Progyny, Inc. (PGNY) Stock Up +12.13% Today?
Key Takeaways
- Progyny shares surged +12.13% to $33.75, up $3.65 from the prior session's close of $30.10.
- The primary catalyst was a record third-quarter earnings report that beat estimates, paired with a raised full-year guidance midpoint.
- A record selling season added 1.3 million new covered lives and more than 85 new clients, with near 100% client retention.
- Multiple analysts lifted price targets following the results, fueling the earnings-driven move.
- Traders are now watching whether the rally extends toward the stock's fresh 52-week high and how 2027 guidance shapes up in February.
- Explore Price Targets, Earnings, and Forecast pages for deeper data on this ticker.
- For AI-driven trading signals across thousands of stocks, visit Trending AI Robots.
Opening Summary
Progyny, Inc. (PGNY), a global leader in women's health and family-building benefits solutions, saw its shares climb sharply in Wednesday's session after delivering record third-quarter results and lifting its full-year outlook. The stock traded up 12.13% to $33.75, a gain of $3.65 from the prior closing price of $30.10. Markets attributed the rally to an earnings beat, a record 2027 selling season, and a wave of bullish analyst revisions following the report.
Record Earnings and a Raised Full-Year Outlook
The immediate catalyst was Progyny's third-quarter report, released after Tuesday's close. Revenue rose 8.9% year over year to $341.25 million, while adjusted earnings per share came in at $0.52, modestly ahead of the consensus estimate of roughly $0.51. The company described the quarter as record-setting across revenue, gross profit, adjusted EBITDA, and net income.
Management reinforced the upbeat tone by raising the midpoint of its full-year 2026 guidance. Revenue is now projected in a range of $1.365 billion to $1.385 billion, with adjusted EBITDA of $235 million to $240 million and adjusted EPS of $2.09 to $2.13. The fourth-quarter outlook, calling for adjusted EPS of $0.53 to $0.58 on revenue of $344.7 million to $364.7 million, also signaled continued momentum into year-end.
Record Selling Season Signals Strong 2027 Momentum
Beyond the headline numbers, investors focused on the strength of Progyny's annual selling season. The company added a record 1.3 million new covered lives and more than 85 new clients, while maintaining near 100% retention of its existing customer base. Roughly 20% of existing clients expanded their relationships for 2027, and once all new clients are live, Progyny expects to exceed 660 clients representing approximately 8.3 million covered lives. The durability of this customer growth underpinned the market's enthusiasm, as it establishes a firmer revenue base heading into 2027.
Analyst Upgrades Amplify the Rally
The price rally was reinforced by a cluster of analyst price-target increases. Wells Fargo raised its target to $38, citing strong sales growth and favorable prospects for 2027, while Citizens moved its target to $38 from $33 and Cantor Fitzgerald lifted its target to $35 from $31. The consensus view among analysts remains bullish, reflecting confidence that Progyny's proven model is gaining share in a consolidating fertility and family-building benefits market.
Market Context and Trading Activity
The move pushed Progyny's shares into fresh 52-week high territory, a notable technical development that can draw additional momentum-driven buying. Trading activity was elevated as investors positioned around the earnings catalyst and subsequent analyst commentary. The rally was company-specific rather than a broad sector re-rating, driven primarily by Progyny's own fundamental results and guidance rather than a synchronized move across healthcare or benefits-management peers.
What Comes Next for PGNY
Looking ahead, investors will watch how the record 2027 selling season translates into actual covered lives going live, with a meaningful portion of new members expected to launch mid-year 2027 rather than at the start of the year. Management has signaled it will provide formal 2027 guidance when it reports year-end results in February, leaving some uncertainty about the trajectory of growth and margins. Key risks include ongoing medical cost inflation, competitive pressures in the fertility benefits space, and slightly lower utilization expectations for a large public-sector client. The company's disciplined share-repurchase program and strong cash generation, however, provide a supportive backdrop as the story evolves.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of automated approaches to explore. Visit the page to see which AI strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PGNY's RSI Indicator ascending out of oversold territory
The RSI Indicator for PGNY moved out of oversold territory on September 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 40 of the 42 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on PGNY as a result. In 73 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for PGNY just turned positive on October 07, 2026. Looking at past instances where PGNY's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
PGNY moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PGNY crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +3.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGNY advanced for three days, in 231 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 160 of 214 cases where PGNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
PGNY broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating fairly steady price growth. PGNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 53 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PGNY's P/B Ratio (5.818) is slightly higher than the industry average of (3.512). P/E Ratio (35.802) is within average values for comparable stocks, (126.100). PGNY's Projected Growth (PEG Ratio) (0.090) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. PGNY's P/S Ratio (1.816) is very high in comparison to the industry average of (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools
Industry ManagedHealthCare
Advertisement